M. J. Thun, E. J. Jacobs, and C. Patrono, The role of aspirin in cancer prevention, Nat. Rev. Clin. Oncol, vol.9, pp.259-267, 2012.

P. Patrignani and . Patrono, C. Aspirin and Cancer. J. Am. Coll. Cardiol, vol.68, pp.967-976, 2016.

P. Patrignani and C. Patrono, Aspirin, platelet inhibition and cancer prevention, Platelets, vol.29, pp.779-785, 2018.

M. Z. Wojtukiewicz, D. Hempel, E. Sierko, S. C. Tucker, and K. V. Honn, Antiplatelet agents for cancer treatment: A real perspective or just an echo from the past?, Cancer Metastasis Rev, vol.36, pp.305-329, 2017.

X. R. Xu, G. M. Yousef, and H. Ni, Cancer and platelet crosstalk: Opportunities and challenges for aspirin and other antiplatelet agents, Blood, vol.131, pp.1777-1789, 2018.

D. A. Drew, Y. Cao, and A. T. Chan, Aspirin and colorectal cancer: The promise of precision chemoprevention, Nat. Rev. Cancer, vol.16, pp.173-186, 2016.

A. Bruno, M. Dovizio, S. Tacconelli, A. Contursi, P. Ballerini et al., Antithrombotic Agents and Cancer, Cancers, vol.10, 2018.

K. ;. Bibbins-domingo, Preventive Services Task Force. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement, Ann. Intern. Med, vol.164, pp.836-845, 2016.

F. M. Giardiello, J. I. Allen, J. E. Axilbund, C. R. Boland, C. A. Burke et al., Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer, Gastroenterology, vol.147, pp.502-526, 2014.

, NICE Guideline on Colorectal Cancer: Diagnosis and Management, p.24, 2019.

L. Bowman, M. Mafham, K. Wallendszus, W. Stevens, G. Buck et al., Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus, N. Engl. J. Med, vol.379, pp.1529-1539, 2018.

J. M. Gaziano, C. Brotons, R. Coppolecchia, C. Cricelli, H. Darius et al., Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): A randomised, double-blind, placebo-controlled trial, Lancet, vol.392, pp.1036-1046, 2018.

J. J. Mcneil, M. R. Nelson, R. L. Woods, J. E. Lockery, R. Wolfe et al., Effect of Aspirin on All-Cause Mortality in the Healthy Elderly, N. Engl. J. Med, vol.379, pp.1519-1528, 2018.

G. A. Kune, S. Kune, and L. F. Watson, Colorectal cancer risk, chronic illnesses, operations, and medications: Case control results from the Melbourne Colorectal Cancer Study, Cancer Res, vol.48, pp.4399-4404, 1988.

E. J. Jacobs, M. J. Thun, E. B. Bain, C. Rodriguez, S. J. Henley et al., A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence, J. Natl. Cancer Inst, vol.99, pp.608-615, 2007.

S. Friis, A. H. Riis, R. Erichsen, J. A. Baron, and H. T. Sørensen, Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drug Use and Colorectal Cancer Risk: A Population-Based, Case-Control Study, Ann. Intern. Med, vol.163, pp.347-355, 2015.

Y. Cao, R. Nishihara, K. Wu, M. Wang, S. Ogino et al., Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer, JAMA Oncol, vol.2, pp.762-769, 2016.

E. Vilar, K. C. Maresso, and E. T. Hawk, Aspirin for Cancer Prevention: One Step Closer, JAMA Oncol, vol.2, pp.770-771, 2016.

T. Stürmer, R. J. Glynn, I. M. Lee, J. E. Manson, J. E. Buring et al., Aspirin use and colorectal cancer: Post-trial follow-up data from the Physicians' Health Study, Ann. Intern. Med, vol.128, pp.713-720, 1998.

N. R. Cook, I. Lee, J. M. Gaziano, D. Gordon, P. M. Ridker et al., Low-dose aspirin in the primary prevention of cancer: The Women's Health Study: A randomized controlled trial, JAMA, vol.294, pp.47-55, 2005.

N. R. Cook, I. Lee, S. M. Zhang, M. V. Moorthy, and J. E. Buring, Alternate-day, low-dose aspirin and cancer risk: Long-term observational follow-up of a randomized trial, Ann. Intern. Med, vol.159, pp.77-85, 2013.

R. Peto, R. Gray, R. Collins, K. Wheatley, C. Hennekens et al., Randomised trial of prophylactic daily aspirin in British male doctors, Br. Med. J. (Clin. Res. Ed.), vol.296, pp.313-316, 1988.

B. Farrell, J. Godwin, S. Richards, and C. Warlow, The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Final results, J. Neurol. Neurosurg. Psychiatry, vol.54, pp.1044-1054, 1991.

E. Flossmann and P. M. Rothwell, British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: Consistent evidence from randomised and observational studies, Lancet, vol.369, pp.1603-1613, 2007.

P. M. Rothwell, M. Wilson, C. Elwin, B. Norrving, A. Algra et al., Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials, Lancet, vol.376, pp.1741-1750, 2010.

J. Chubak, E. P. Whitlock, S. B. Williams, A. Kamineni, B. U. Burda et al., Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the U.S. Preventive Services Task Force, Ann. Intern. Med, vol.164, pp.814-825, 2016.

J. Cuzick, M. A. Thorat, C. Bosetti, P. H. Brown, J. Burn et al., Estimates of benefits and harms of prophylactic use of aspirin in the general population, Ann. Oncol, vol.26, pp.47-57, 2015.

A. M. Algra and P. M. Rothwell, Effects of regular aspirin on long-term cancer incidence and metastasis: A systematic comparison of evidence from observational studies versus randomised trials, Lancet Oncol, vol.13, pp.518-527, 2012.

H. Nan, C. M. Hutter, Y. Lin, E. J. Jacobs, C. M. Ulrich et al., Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants, JAMA, vol.313, pp.1133-1142, 2015.

M. J. Thun, M. M. Namboodiri, and C. W. Heath, Aspirin use and reduced risk of fatal colon cancer, N. Engl. J. Med, vol.325, pp.1593-1596, 1991.

E. P. Whitlock, B. U. Burda, S. B. Williams, J. M. Guirguis-blake, and C. V. Evans, Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force, Ann. Intern. Med, vol.164, pp.826-835, 2016.

S. P. Dehmer, M. V. Maciosek, T. J. Flottemesch, A. B. Lafrance, and E. P. Whitlock, Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force, Ann. Intern. Med, vol.164, pp.777-786, 2016.

J. A. Baron, B. F. Cole, R. S. Sandler, R. W. Haile, D. Ahnen et al., A randomized trial of aspirin to prevent colorectal adenomas, N. Engl. J. Med, vol.348, pp.891-899, 2003.

R. S. Sandler, S. Halabi, J. A. Baron, S. Budinger, E. Paskett et al., A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer, N. Engl. J. Med, vol.348, pp.883-890, 2003.

R. F. Logan, M. J. Grainge, V. C. Shepherd, N. C. Armitage, K. R. Muir et al., Aspirin and folic acid for the prevention of recurrent colorectal adenomas, Gastroenterology, vol.134, pp.29-38, 2008.

R. Benamouzig, J. Deyra, A. Martin, B. Girard, E. Jullian et al., Daily soluble aspirin and prevention of colorectal adenoma recurrence: One-year results of the APACC trial, Gastroenterology, vol.125, pp.328-336, 2003.

B. F. Cole, R. F. Logan, S. Halabi, R. Benamouzig, R. S. Sandler et al., Aspirin for the chemoprevention of colorectal adenomas: Meta-analysis of the randomized trials, J. Natl. Cancer Inst, vol.101, pp.256-266, 2009.

H. Ishikawa, M. Mutoh, S. Suzuki, S. Tokudome, Y. Saida et al., The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: A randomised trial, Gut, vol.63, pp.1755-1759, 2014.

H. Pommergaard, J. Burcharth, J. Rosenberg, and H. Raskov, Aspirin, Calcitriol, and Calcium Do Not Prevent Adenoma Recurrence in a Randomized Controlled Trial, Gastroenterology, vol.150, pp.114-122, 2016.

M. A. Hull, K. Sprange, T. Hepburn, W. Tan, A. Shafayat et al., Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): A multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial, Lancet, vol.392, pp.2583-2594, 2018.

, Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk, Lancet, vol.351, pp.233-241, 1998.

. The-salt-collaborative and . Group, Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events, Lancet, vol.338, pp.1345-1349, 1991.

H. T. Lynch, C. L. Snyder, T. G. Shaw, C. D. Heinen, and M. P. Hitchins, Milestones of Lynch syndrome, Nat. Rev. Cancer, vol.15, pp.181-194, 2015.

J. Burn, D. T. Bishop, J. Mecklin, F. Macrae, G. Möslein et al., Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome, N. Engl. J. Med, vol.359, pp.2567-2578, 2008.

J. Burn, A. Gerdes, F. Macrae, J. Mecklin, G. Moeslein et al., Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the CAPP2 randomised controlled trial, Lancet, vol.378, pp.2081-2087, 2011.

A. Ouakrim, D. Dashti, S. G. Chau, R. Buchanan, D. D. Clendenning et al., Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome, J. Natl. Cancer Inst, vol.107, 2015.

D. C. Farrow, T. L. Vaughan, P. D. Hansten, J. L. Stanford, H. A. Risch et al., Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer, Cancer Epidemiol. Biomark. Prev, vol.7, pp.97-102, 1998.

L. Sharp, C. E. Chilvers, K. K. Cheng, P. A. Mckinney, R. F. Logan et al., Risk factors for squamous cell carcinoma of the oesophagus in women: A case-control study, Br. J. Cancer, vol.85, pp.1667-1670, 2001.

C. C. Abnet, N. D. Freedman, F. Kamangar, M. F. Leitzmann, A. R. Hollenbeck et al., Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: Results from a cohort study and a meta-analysis, Br. J. Cancer, vol.100, pp.551-557, 2009.

E. M. Funkhouser and G. B. Sharp, Aspirin and reduced risk of esophageal carcinoma, Cancer, vol.76, pp.1116-1119, 1995.

D. Zaridze, E. Borisova, D. Maximovitch, and V. Chkhikvadze, Aspirin protects against gastric cancer: Results of a case-control study from, Int. J. Cancer, vol.82, pp.473-476, 1999.

D. M. Schreinemachers and R. B. Everson, Aspirin use and lung, colon, and breast cancer incidence in a prospective study, Epidemiology, vol.5, pp.138-146, 1994.

D. Feskanich, C. Bain, A. T. Chan, N. Pandeya, F. E. Speizer et al., Aspirin and lung cancer risk in a cohort study of women: Dosage, duration and latency, Br. J. Cancer, vol.97, pp.1295-1299, 2007.

R. E. Harris, J. Beebe-donk, and G. A. Alshafie, Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: Results of a case control study, Int. J. Biol. Sci, vol.3, pp.328-334, 2007.

S. Ye, M. Lee, D. Lee, E. Ha, and E. M. Chun, Association of Long-term Use of Low-Dose Aspirin as Chemoprevention with Risk of Lung Cancer, JAMA Netw. Open, vol.2, 2019.

T. Luo, H. Yan, P. He, Y. Luo, Y. Yang et al., Aspirin use and breast cancer risk: A meta-analysis, Breast Cancer Res. Treat, vol.131, pp.581-587, 2012.

R. D. Kehm, J. L. Hopper, E. M. John, K. Phillips, R. J. Macinnis et al., Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: A cohort study, Breast Cancer Res, vol.21, 2019.

L. Lu, L. Shi, J. Zeng, and Z. Wen, Aspirin as a potential modality for the chemoprevention of breast cancer: A dose-response meta-analysis of cohort studies from 857,831 participants, Oncotarget, vol.8, pp.40389-40401, 2017.

S. Zhong, L. Chen, X. Zhang, D. Yu, J. Tang et al., Aspirin use and risk of breast cancer: Systematic review and meta-analysis of observational studies, Cancer Epidemiol. Biomark. Prev, vol.24, pp.1645-1655, 2015.

P. M. Rothwell, J. F. Price, F. G. Fowkes, A. Zanchetti, M. C. Roncaglioni et al., Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised controlled trials, Lancet, vol.379, pp.1602-1612, 2012.

S. L. Zheng and A. J. Roddick, Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis, JAMA, vol.321, pp.277-287, 2019.

P. M. Rothwell, F. G. Fowkes, J. F. Belch, H. Ogawa, C. P. Warlow et al., Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomised trials, Lancet, vol.377, pp.31-41, 2011.

S. R. Seshasai, S. Wijesuriya, R. Sivakumaran, S. Nethercott, S. Erqou et al., Effect of aspirin on vascular and nonvascular outcomes: Meta-analysis of randomized controlled trials, Arch. Intern. Med, vol.172, pp.209-216, 2012.

E. J. Mills, P. Wu, M. Alberton, S. Kanters, A. Lanas et al., Low-dose aspirin and cancer mortality: A meta-analysis of randomized trials, Am. J. Med, vol.125, pp.560-567, 2012.

P. M. Rothwell, M. Wilson, J. F. Price, J. F. Belch, T. W. Meade et al., Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials, Lancet, vol.379, pp.1591-1601, 2012.

P. C. Elwood, J. E. Pickering, G. Morgan, J. Galante, A. L. Weightman et al., Systematic review update of observational studies further supports aspirin role in cancer treatment: Time to share evidence and decision-making with patients?, PLoS ONE, vol.13, 2018.

A. Lipton, S. Scialla, H. Harvey, R. Dixon, R. Gordon et al., Adjuvant antiplatelet therapy with aspirin in colo-rectal cancer, J. Med, vol.13, pp.419-429, 1982.

B. Lebeau, C. Chastang, J. F. Muir, J. Vincent, F. Massin et al., The "Petites Cellules" Group. No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy, vol.71, pp.1741-1745, 1993.

E. T. Creagan, D. I. Twito, S. L. Johansson, D. J. Schaid, P. S. Johnson et al., A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma, J. Clin. Oncol, vol.9, pp.2104-2109, 1991.

W. Y. Chen, E. P. Winer, W. T. Barry, A. H. Partridge, L. A. Carey et al., ABC trial (A011502): Randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for breast cancer, J. Clin. Oncol, vol.36, 2018.

R. Ali, H. Toh, and W. Chia, ASCOLT Trial Investigators. The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer-The ASCOLT study: Study protocol for a randomized controlled trial, Trials, vol.12, 2011.

C. Coyle, F. H. Cafferty, S. Rowley, M. Mackenzie, L. Berkman et al., ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours, Contemp. Clin. Trials, vol.51, pp.56-64, 2016.

D. A. Drew, S. M. Chin, K. K. Gilpin, M. Parziale, E. Pond et al., ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): A study protocol for a randomized controlled trial, Trials, vol.18, 2017.

P. Ballerini, M. Dovizio, A. Bruno, S. Tacconelli, and P. Patrignani, P2Y12 Receptors in Tumorigenesis and Metastasis, Front. Pharmacol, vol.9, p.66, 2018.

P. Gresele, M. Malvestiti, and S. Momi, Anti-platelet treatments in cancer: Basic and clinical research, Thromb. Res, vol.164, pp.106-111, 2018.

L. C. Soriano, M. Soriano-gabarró, and L. A. Rodríguez, The Protective Effect of Low-Dose Aspirin against Colorectal Cancer Is Unlikely Explained by Selection Bias: Results from Three Different Study Designs in Clinical Practice, PLOS ONE, vol.11, 2016.

A. Leader, R. Zelikson-saporta, D. Pereg, G. Spectre, U. Rozovski et al., The Effect of Combined Aspirin and Clopidogrel Treatment on Cancer Incidence, Am. J. Med, vol.130, pp.826-832, 2017.

A. Rodríguez-miguel, L. A. García-rodríguez, M. Gil, H. Montoya, S. Rodríguez-martín et al., Clopidogrel and Low-Dose Aspirin, Alone or Together, Reduce Risk of Colorectal Cancer, Clin. Gastroenterol. Hepatol, vol.17, pp.2024-2033, 2018.

S. Raposeiras-roubín, E. Abu-assi, I. Muñoz-pousa, M. Cespón-fernández, R. Cobas-paz et al., Risk of cancer after an acute coronary syndrome according to the type of P2Y12 inhibitor, Thromb. Res, vol.174, pp.51-58, 2019.

V. L. Serebruany, V. Cherepanov, H. A. Cabrera-fuentes, and M. H. Kim, Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges, Thromb. Haemost, vol.114, pp.1104-1112, 2015.

V. L. Serebruany, V. Cherepanov, E. Z. Golukhova, and M. H. Kim, The Dual Antiplatelet Therapy Trial after the FDA Update: Noncardiovascular Deaths, Cancer and Optimal Treatment Duration, Cardiology, vol.132, pp.74-80, 2015.

. Caprie-steering-committee, CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE), Lancet, vol.348, pp.1329-1339, 1996.

D. L. Bhatt, K. A. Fox, W. Hacke, P. B. Berger, H. R. Black et al., Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events, N. Engl. J. Med, vol.354, pp.1706-1717, 2006.

S. Yusuf, F. Zhao, S. R. Mehta, S. Chrolavicius, G. Tognoni et al., Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, N. Engl. J. Med, vol.345, pp.494-502, 2001.

S. R. Steinhubl, P. B. Berger, J. T. Mann, E. T. Fry, A. Delago et al., Clopidogrel for the Reduction of Events during Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial, JAMA, vol.288, pp.2411-2420, 2002.

S. D. Wiviott, E. Braunwald, C. H. Mccabe, G. Montalescot, W. Ruzyllo et al., Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes, N. Engl. J. Med, vol.357, 2001.

E. F. Unger, Weighing Benefits and Risks-The FDA's Review of Prasugrel, N. Engl. J. Med, vol.361, pp.942-945, 2009.

L. Mauri, D. J. Kereiakes, R. W. Yeh, P. Driscoll-shempp, D. E. Cutlip et al., Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents, N. Engl. J. Med, vol.371, pp.2155-2166, 2014.

M. T. Roe, P. W. Armstrong, K. A. Fox, H. D. White, D. Prabhakaran et al., Prasugrel versus clopidogrel for acute coronary syndromes without revascularization, N. Engl. J. Med, vol.367, pp.1297-1309, 2012.

M. T. Roe, D. D. Cyr, D. Eckart, P. J. Schulte, M. A. Morse et al., Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome, Eur. Heart J, vol.37, pp.412-422, 2016.

R. A. Kotronias, C. S. Kwok, C. W. Wong, T. Kinnaird, A. Zaman et al., Cancer Event Rate and Mortality with Thienopyridines: A Systematic Review and Meta-Analysis, Drug Saf, vol.40, pp.229-240, 2017.

S. Elmariah, G. Doros, O. R. Benavente, D. L. Bhatt, S. J. Connolly et al., Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis, Circ. Cardiovasc. Interv, vol.11, 2018.

P. Tricoci, Z. Huang, C. Held, D. J. Moliterno, P. W. Armstrong et al., Thrombin-receptor antagonist vorapaxar in acute coronary syndromes, N. Engl. J. Med, vol.366, pp.20-33, 2012.

D. A. Morrow, E. Braunwald, M. P. Bonaca, S. F. Ameriso, A. J. Dalby et al., Vorapaxar in the secondary prevention of atherothrombotic events, N. Engl. J. Med, vol.366, pp.1404-1413, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00932160

B. M. Hicks, L. J. Murray, C. Hughes, and C. R. Cardwell, Clopidogrel use and cancer-specific mortality: A population-based cohort study of colorectal, breast and prostate cancer patients, Pharmacoepidemiol. Drug Saf, vol.24, pp.830-840, 2015.

, This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, © 2019 by the authors. Licensee MDPI